经济学人中英文版VIP免费

Taking its medicine.自尝苦果。 A drug giant coughs up to settle bribery charges. 一个制药巨头被迫出钱就撤销行贿指控与司法部达成和解。 IN AMERICA, it was once common for drug firms to offer doctors "perks" to encourage them to prescribe theirpills. Regulators now frown on such iffy sales techniques, and drug firms have more or less stopped using them.But in emerging markets, it is a different story, as a settlement on August 7th between America's Department ofJustice and Pfizer, a big American drug firm, made clear. 在美国，制药公司给医生"回扣"鼓励他们开处方时使用该公司生产的药物曾是很常见的事。 现在相关管理部门开始禁止这样不规范的销售技巧，因此一些制药公司也或多或少不再使用这种技巧。 8 月 7 日，美国大型制药公司辉瑞就海外贿赂行为与美国司法部达成了和解，此事正好表明新兴市场的情况与美国的有所不同。 In China Pfizer established a "club" that provided "high-prescribing" doctors with all kinds of entertainmentunder the guise of attending conferences. In Kazakhstan Pfizer awarded an exclusive distribution deal to a local firmafter it was told there was no other way to secure government approval for a Pfizer product. 辉瑞公司在中国成立了一个"俱乐部"，该俱乐部以开会的名义邀请那些"开药量较大"的医生参加各种娱乐活动。 辉瑞公司还与哈萨克斯坦一家当地公司签订了独家经销协议，因为此前辉瑞得知，除此之外没有其他的办法可以获得哈萨克斯坦政府对辉瑞制药的批准。 Unfortunately for Pfizer, such acts violated the Foreign Corrupt Practices Act (FCPA), an American law thatcriminalises bribery abroad. Doctors in many of the countries in question are state employees, making the giftsbribes to government officials. This week Pfizer agreed to pay a fine to settle corruption charges and to disgorgerelated illegally earned profits to the Securities and Exchange Commission. The settlement, which will cost ...